文献速递胸部肿瘤

美国学术中心与社区中心IV期肺癌患者生存比较

Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States.
PubMed 文献 · J Thorac Oncol · 2018-10-09

该回顾性分析利用美国国家癌症数据库1998至2010年193,279例IV期非小细胞肺癌患者,比较学术中心与社区中心的2年生存。结果显示学术中心2年生存率增长幅度更大,腺癌尤为明显,提示治疗相关差异可能存在。

要点

  • 学术中心2年生存率从1998年11.5%升至2010年17.4%,社区中心从9.2%升至13.1%。
  • 腺癌2年生存学术中心与社区中心差异从1998年+3.2%扩大至2010年+5%。
  • 鳞癌2年生存学术中心与社区中心差异从1998年+0.3%扩大至2010年+7.2%。

核心结论

  • 学术中心较社区中心在1998至2010年间2年生存率增长更大,腺癌尤为明显。
  • 研究提示学术中心与社区中心之间可能存在治疗相关差异。

研究设计与样本

  • 回顾性分析美国国家癌症数据库1998至2010年数据,纳入193,279例IV期非小细胞肺癌患者。
  • 主要终点为2年生存,采用多变量回归模型控制年龄、诊断年份、性别、支付方、组织学类型和机构类型。

主要发现

  • 学术中心2年生存率1998年为11.5%,社区中心为9.2%;2010年分别为17.4%和13.1%。
  • 多变量分析确认1998至2010年学术中心较社区中心2年生存相对增加显著(p=0.0005)。
  • 腺癌与鳞癌2年生存差异从1998年10.2%对9.9%扩大至2010年17.3%对10.1%。
  • 腺癌学术中心与社区中心2年生存差异从1998年12.3%对9.1%扩大至2010年20.5%对15.5%(多变量模型p=0.005)。

临床怎么用

  • 临床应关注IV期非小细胞肺癌在不同治疗机构间的生存差异,尤其是腺癌患者。
  • 需进一步研究验证差异并改善各治疗机构患者的生存。

局限性

  • 本研究为回顾性数据库分析,可能存在未控制混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Although metastatic NSCLC is widely treated in both academic centers (ACs) and community-based centers (CCs), it is unclear whether outcomes are similar across both settings. A growing variety of chemotherapies and targeted agents for an increasingly histology- and molecular-based treatment strategy could provide an advantage to patients treated in ACs. Using the National Cancer Database, we investigated whether treatment at ACs was associated with a survival advantage in metastatic NSCLC. METHODS: We conducted a retrospective analysis of the National Cancer Database after the introduction of novel NSCLC chemotherapy agents from 1998 to 2010. The primary outcome was 2-year survival, which was analyzed by using a multivariable regression model controlling for age, year of diagnosis, sex, primary payer, histologic type, facility type (AC versus CC), and an interaction term allowing a time-based comparison of survival between ACs and CCs. Alpha was set to 0.001 because of the size of the data set. RESULTS: There were 193,279 patients included in this study. The percentage of patients achieving 2-year survival was higher in ACs versus in CCs in 1998 (11.5% versus 9.2% [+2.3%]), and by 2010, the difference had increased to 17.4% versus 13.1% (+4.3%). Multivariable analysis confirmed a significant relative increase in 2-year survival associated with ACs versus with CCs from 1998 to 2010 (p = 0.0005). A histology-dependent survival difference was also noted in adenocarcinoma versus in squamous cell carcinoma (10.2% versus 9.9% in 1998 [+0.3%], increasing to 17.3% versus 10.1% in 2010 [+7.2%]). Adenocarcinoma survival also varied by treatment facility, with the difference in 2-year survival in ACs versus in CCs increasing from 12.3% versus 9.1% (+3.2%) in 1998 to 20.5% versus 15.5% (+5%) in 2010, with a trend toward significance in our multivariable model (p = 0.005). CONCLUSIONS: A greater increase in survival was noted in ACs than in CCs over this time period, and it was particularly pronounced among patients with adenocarcinoma versus in those with squamous cell carcinoma. Given the known advances in adenocarcinoma treatment compared with in squamous cell lung cancer over this time period, our study suggests that potential treatment-related disparities may exist between ACs and CCs. Further study will be needed to validate this disparity in health care and address opportunities to improve survival in patients with stage IV NSCLC across treatment settings.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Ramalingam S, Dinan MA, Crawford J, et al. Survival Comparison in Patients with Stage IV Lung Cancer in Academic versus Community Centers in the United States. J Thorac Oncol. 2018. PMID: 30312680. doi:10.1016/j.jtho.2018.09.007

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。